Physician profile
John Bowers
NPI 1902218001
$1,294.31
in general payments reported to CMS, 2019-2025
27 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.54 · 2023: $221 · 2024: $640 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,275.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $281.12 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $136.20 | 2023-2025 | Tagrisso, Lynparza, Enhertu |
| Janssen Biotech, INC. | $71.69 | 2023-2025 | Erleada |
| Sobi, INC | $71.04 | 2024-2025 | |
| Daiichi Sankyo INC. | $68.87 | 2024-2025 | Enhertu, Vanflyta |
| Exelixis INC. | $60.56 | 2024 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $57.43 | 2024-2025 | Alunbrig, Fruzaqla |
| Genentech USA, INC. | $45.59 | 2024 | Phesgo, Perjeta, Itovebi |
| Incyte Corporation | $38.85 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Karyopharm Therapeutics INC. | $37.00 | 2024-2025 | Xpovio |
| Merck Sharp & Dohme LLC | $36.39 | 2024 | Keytruda |
| Astellas Pharma US INC | $36.04 | 2019-2025 | Xtandi |
| Siemens Medical Solutions USA, INC. | $35.44 | 2025 | Truebeam |
| Jazz Pharmaceuticals INC. | $33.95 | 2023-2024 | Zepzelca |
| Seagen INC. | $32.65 | 2023 | Adcetris |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $32.32 | 2024-2025 | Epkinly |
| Glaxosmithkline, LLC. | $30.47 | 2025 | Ojjaara, Trelegy Ellipta |
| Geron Corporation | $25.75 | 2024 | Rytelo |
| Tersera Therapeutics LLC | $24.01 | 2024 | Zoladex |
| Aveo Pharmaceuticals, INC. | $22.48 | 2025 | |
| Eisai INC. | $21.99 | 2024 | |
| Genzyme Corporation | $18.43 | 2024 | |
| Lilly USA, LLC | $18.18 | 2024 | Retevmo, Jaypirca, Verzenio |
| Adc Therapeutics America, INC. | $15.22 | 2025 | |
| Beone Medicines USA, INC. | $14.67 | 2025 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $14.15 | 2024 | |
| Pfizer INC. | $13.82 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.